Antibacterial Agents TRIZ Cases

Antibodies bind hepcidin to increase circulating iron, addressing inadequate modulation of iron homeostasis in current treatments.

Dissolving vanadium oxide clusters with polyhexamethylene biguanide eliminates complex heating steps while maintaining broad-spectrum antiviral activity.

Enterococcus mundtii strain ST4SA produces peptide ST4SA to inhibit pathogens while maintaining stability under intestinal stress conditions.

Engineered DVD-Ig proteins resolve molecular heterogeneity by using complementary cysteine residues to enforce correct heavy-light chain pairing.

Modified FN3 domain binding molecules neutralize staphylococcal leukotoxins while evading protein A and Sbi binding mechanisms.

Maternal DHA administration lowers infant obesity risk by balancing omega fatty acids to prevent excessive early weight gain.

A mask integrates a radiation-generating layer that ionizes ambient water to produce hydroxyl radicals.

Halogenated benzimidazolium salts reduce permeability for effective topical lung treatment of chronic bronchitis and asthma.

Targeting conserved coagulase antigens provides broad-spectrum immunity against diverse Staphylococcus strains while avoiding antibiotic resistance.

A lentiviral vector vaccine product induces robust humoral and cellular immune responses through a coordinated prime/boost regimen.

Jet-milled clofazimine particles target alveolar macrophages to resolve systemic toxicity and slow onset issues in tuberculosis treatment.

Heat shock protein fusions bind biotinylated antigens to form self-assembling complexes that stimulate cellular immunity.

Neat ionic liquids enhance skin penetration while disrupting bacterial biofilms to treat antibiotic-resistant infections.

Immunogenic compositions comprising deacetylated PNAG polysaccharide conjugates linked to carrier proteins.

Solid-phase peptide synthesis modifies specific residues in daptomycin, overcoming structural limitations of fermentation to improve antibacterial activity.

PAX peptides uncouple antibacterial potency from host toxicity by using N-cas amino acids to selectively target multidrug-resistant bacteria.

Controlled low oxygen levels resolve the contradiction between high productivity and production consistency in diphtheria toxin manufacturing.

Novel indolizine derivatives bypass resistance mechanisms in multidrug-resistant strains through a distinct molecular mechanism of action.

Peptide compositions kill multidrug-resistant bacteria and recruit immune cells to infection sites.

Fermentable galactooligosaccharides reduce inflammatory markers and insulin levels, addressing inadequate cardiovascular risk management.

Enzymatic pathway replaces complex chemical synthesis to produce hybrid lincosamides with enhanced antimicrobial activity.

CPPT activation of sized polysaccharides enables stable meningococcal conjugates, resolving low yield and purity issues in serogroup X vaccine manufacturing.

Chemical synthesis of Helicobacter pylori serotype O2 oligosaccharides using segmented glycosyl building blocks and optimized glycosylation conditions.

Lipid vesicular carriers encapsulate hydrophobic agents to enhance drug loading and penetration into the pilosebaceous unit while minimizing systemic exposure.

Activated carbon extracts octanoate stabilizers from albumin, restoring binding capacity and enhancing detoxification efficiency for liver disease treatments.

Adsorb mupirocin onto a solid support for subsequent conversion to the calcium salt.

A live attenuated ts19 strain provides protective immunity against enzootic pneumonia in swine.

Replacing viral enhancers with MHC-derived upstream promoters increases transgene expression while eliminating insertional mutagenesis risks.

Diallyl sulphide compounds from garlic extract replace synthetic chemicals to eliminate drug residues and resistance development.

Cyclic dinucleotide analogues modulate the STING pathway to overcome limited immunomodulatory strategies in treating inflammatory diseases.

Single-domain antibodies bind Sap protein monomers to block polymerization, resolving antibiotic limitations by disrupting anthrax S-layer assembly.

Formula I compounds inhibit p38 MAP kinase activity, resolving the contradiction between oral bioavailability and reliable therapeutic efficacy.

Specific C6' and C2' modifications force ring I conformations that overcome aminoglycoside modifying enzymes while minimizing ototoxicity.

pH-dependent polymers shield guanylate cyclase C agonists from acidic stomach environments, ensuring stable delivery to intestinal targets.

Formula I compounds inhibit replicating and non-replicating Mycobacterium tuberculosis, addressing drug resistance and long treatment courses.

A monoclonal antibody binds the HpHSP60 peptide to block immunosuppressive functions and activate host immunity.

Carbonyldiimidazole catalyzes one-pot synthesis of the antimicrobial compound, achieving 83% yield and resolving low-yield trade-offs.

Color-coded polyphosphazene particles eliminate tissue irritation and immune reactions while ensuring uniform suspension in delivery systems.

A thiophene derivative compound specifically inhibits PDE4 enzyme activity to treat inflammatory diseases.

Heating avibactam mixtures under positive pressure yields polymorphically pure form C crystals.

Administering oligosaccharides and essential oils decreases pathogenic E. coli populations in animal gastrointestinal tracts.

Multi-strain SCFA-producing microbial consortia inhibit pathogenic bacteria in animal digestive tracts, reducing antibiotic resistance and mortality.

E. coli polysaccharide antigens covalently bound to detoxified exotoxin A carrier protein induce immune response.

Immune and ligand affinity chromatography isolates homogenous TNF-binding proteins without reductive cleavage, preserving binding activity.

Small molecules bind the LuxN receptor to block autoinducer detection, resolving the lack of targeted quorum sensing interference tools.

A pyridinium ionic liquid catalyzes a one-pot reaction driven by ultrasonic irradiation to produce an imidazole derivative compound.

A fluorescent reporter system screens cyclic peptide inhibitors that modulate the sigmaE pathway, resolving pleiotropic defects from genetic mutations.

Anti-LILRB2 antibodies bind LILRB2 receptors to induce M1 or M2 phenotypes, resolving the trade-off between tumor killing and immune suppression.